Navigation Links
Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
Date:6/18/2009

ward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
2. Novavax Reports First Quarter 2009 Financial Results
3. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
4. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Early Retirement of $17 Million of Convertible Debt
6. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
9. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
11. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... York, NY (PRWEB) September 18, 2014 ... completed negotiations with Salem Realty Group and has acquired ... development space within the Salem Executive Complex adjacent to ... ceremony was held on Friday September 5th. Whitehouse Labs ... refit the entire space specifically for package testing. The ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
(Date:9/17/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... protected regenerative biomaterials and bioimplants processed from human ... clinical study.    The study article, ... Trial Evaluating the Use of Dehydrated ... Therapy vs. Multi-layer Compression Therapy Alone in the ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
... , Strategic Examination and Consolidation of Services Recommended ... 27 Little uniformity exists in the structure or functions of ... to Clinical Trials Offices: What,s New in Research Administration?, ... (AAHC). Emerging centralized clinical trial offices (CTOs) are among the ...
... , , ATLANTA, Aug. 27 ... million extension of its Series C financing which was originally completed in ... $5 million in Series C preferred stock received warrants for an additional ... have up to 30 days from the delivery of Phase III top-line ...
... , , , ... ATLANTA, Aug. 27 Airo, recognized maker of the ... Safe handset is available for delivery Q4 of 2009. Airo ... in potentially explosive environments like Petroleum, Chemicals, Fertilizer, Coal, Propane, ...
Cached Biology Technology:Clinical Trials Offices Changing Academic Health Center Research Infrastructure 2Alimera Sciences Closes $5 Million in Extended Series C Financing 2Airo Wireless Announces the Release of the Intrinsically Safe A25is Cell Phone/PDA 2
(Date:9/17/2014)... significantly faster since the 1960s. The typical development phases ... have accelerated -- by as much as 70 percent. ... by scientists from Technische Universitt Mnchen based on long-term ... observed since 1870. Their findings were published recently in ... dieback" was a hot topic, with the very survival ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
Breaking Biology News(10 mins):Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... July 20, 2011Researchers at the U.S. Department of Energy,s ... Center have found a potential key for unlocking the ... leaves and stalks, or switch grass. In a ... Chemical Society , Los Alamos researchers S. Gnanakaran, Giovanni ...
... sleuthing the 2010 Deepwater Horizon oil spill, a research team ... chemicals were contained in a deep, hydrocarbon-containing plume. The ... mapped and sampled it last summer in the Gulf of ... spill. The researchers took a major step in explaining ...
... Bureau of Reclamation and Fluid Imaging Technologies Inc. have ... the capacity and speed of Fluid Imaging Technologies, FlowCAM ... larvae in water samples. The spread of mussels ... impair or interrupt water delivery and hydropower generation functions ...
Cached Biology News:Researchers find potential key for unlocking biomass energy 2Chemical make-up of Gulf of Mexico plume determined 2Chemical make-up of Gulf of Mexico plume determined 3Chemical make-up of Gulf of Mexico plume determined 4Reclamation signs research agreement to improve quagga and zebra mussel larvae detection 2
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... working in a regulated environment, Pipette ... calibration software that automates gravimetric pipette ... framework that meets todays regulatory compliance ... secure solution that includes a full ...
... of the yolk protein Vtg in plasma from ... sensitive biomarker for endocrine disrupting chemicals (EDCs) with ... become an accepted screening test for the estrogenic ... trout) EIA kit is a double-antibody immunometric (sandwich) ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
Biology Products: